News about "Novo Nordisk"

Emcure Launches Poviztra to Broaden Access to Weight Management Therapy

Emcure has launched Poviztra, a once-weekly weight management therapy available in a pen device across five dosage strengths, with prices starting at INR 8,790 per month, aimed at improving access through convenient and precise dosing.

Novo Nordisk | 22/12/2025 | By News Bureau

Takeda Becomes a BaseLaunch Partner

BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.

Novo Nordisk | 19/12/2025 | By News Bureau

Novo Nordisk Seeks FDA Approval for CagriSema Weight-Loss Therapy

CagriSema 2.4 mg/2.4 mg is an investigational once-weekly injectable combining cagrilintide and semaglutide to target complementary obesity pathways. In the REDEFINE 1 phase III trial, patients with obesity or overweight achieved an average weight loss of 23 percent, reinforcing the company’s ongoing focus on innovation in obesity treatment.

Novo Nordisk | 19/12/2025 | By News Bureau

Novo Nordisk Completes Acquisition of Akero Therapeutics

Novo Nordisk has finalised its acquisition of Akero Therapeutics, making Akero a wholly owned subsidiary. Following the transaction, Akero’s common stock will cease trading on the Nasdaq Global Select Market.

Novo Nordisk | 10/12/2025 | By Akanki

Novo Nordisk Files for FDA Approval of Wegovy Injection 7.2 mg

Novo Nordisk has filed an sNDA with the US FDA for a 7.2 mg dose of Wegovy, aiming to offer a higher-dose option for adults with obesity. The application, supported by STEP UP trial data showing 20.7 percent average weight loss, will be reviewed under the FDA’s expedited CNPV pathway.

Novo Nordisk | 29/11/2025 | By Dineshwori |  170

Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India

Under this agreement, Emcure becomes the first Indian company to hold exclusive rights for the distribution and commercialisation of the drug, expanding access to Novo Nordisk’s innovative semaglutide therapy for people living with overweight and obesity in the country.

Novo Nordisk | 10/11/2025 | By Dineshwori |  274

Novo Nordisk Confirms No Further Proposal Increase for Metsera Acquisition

Novo Nordisk has confirmed that it will not increase its offer to acquire Metsera, ending speculation of a potential bidding escalation.

Novo Nordisk | 10/11/2025 | By Dineshwori |  102

Novo Nordisk Submits Updated Proposal to Acquire Metsera in Multi-Billion-Dollar Deal

Novo Nordisk has confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera, which has been declared superior by Metsera’s board of directors.

Novo Nordisk | 06/11/2025 | By Dineshwori |  110

Novo Nordisk Makes Unsolicited USD 6.5 Billion Bid to Acquire Metsera

Novo Nordisk, a leading global healthcare company founded in 1923 and headquartered in Denmark, has announced that it has submitted an unsolicited proposal to acquire Metsera, Inc.

Novo Nordisk | 01/11/2025 | By Darshana |  134

FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes

Rybelsus (Semaglutide) tablets, available in 7 mg and 14 mg doses, is the only FDA-approved oral GLP-1 therapy, and is now indicated to lower the risk of Major Adverse Cardiovascular Events (MACE)—including CV death, heart attack, or stroke—in adults with type 2 diabetes at high cardiovascular risk.

Novo Nordisk | 21/10/2025 | By Dineshwori |  152